MAGEA3 and sarcoma: We performed immunohistochemistry (IHC) on DDLS and WDLS to confirm protein expression of TTK, PBK and SPA17, as well as CTAs commonly expressed in sarcoma including NY-ESO-1 (included in Nanostring panel as CTAG1B), SSX2 and MAGE-A3, some of which that have been targeted by adoptive cell therapy18,36.